熱門資訊> 正文
Ideaya Biosciences报告了Darovasertib联合辉瑞克唑替尼1X治疗转移性葡萄膜黑色素瘤的I/II期试验（OptimUM-01）的中位总生存期结果
2025-10-20 18:12
- Combination demonstrated median overall survival (OS) of 21.1 months, compared to reported historical mOS of approximately 12 months in published meta-analysis of metastatic uveal melanoma in the first-line setting
- Median progression free survival (PFS) of 7.0 months
- Confirmed overall response rate (ORR) by RECIST 1.1 of 34%, median duration of response (mDOR) of 9 months and disease control rate (DCR) of 90%
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
